REMAP-ILD has the potential to revolutionise the way clinical trials are run and help find treatments faster.
We need to move quickly and effectively to transform patients’ lives as rapidly as possible. Discover more information on this website about this ambitious project.
When fibrotic ILD progress, patients have increasing symptoms that limit everyday activities and often need oxygen therapy - having devastating impact on quality of life.
In a REMAP trial, many different treatments and combinations of treatments can be tested at the same time, and the results can be understood sooner.
We are growing a worldwide REMAP-ILD community of patients and caregivers, biotech firms, academics, researchers and clinicians. Securing funding is critical to the next stage of the project.
It is a collaborative project involving ILD experts from around the world, bringing together scientists, clinicians, patients, patient organisations and industry.
Read more